Oncotarget

Research Papers:

Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis

Pin Wu, Dang Wu, Lufeng Zhao, Lijian Huang, Gang Shen, Jian Huang and Ying Chai _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:19863-19883. https://doi.org/10.18632/oncotarget.7887

Metrics: PDF 3604 views  |   HTML 4830 views  |   ?  


Abstract

Pin Wu1,4,*, Dang Wu2,4,*, Lufeng Zhao1, Lijian Huang1, Gang Shen1, Jian Huang3,4, Ying Chai1

1Department of Thoracic Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China

2Department of Radiation Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China

3Department of Surgical Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China

4Cancer Institute, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China

*These authors contributed equally to this work

Correspondence to:

Ying Chai, e-mail: [email protected]

Pin Wu, e-mail: [email protected]

Keywords: STAT3, solid tumors, prognosis, overall survival, disease free survival

Received: October 12, 2015     Accepted: February 13, 2016     Published: March 03, 2016

ABSTRACT

Accumulated studies have provided controversial evidences of the association between signal transducer and activator of transcription proteins 3 (STAT3) expression and survival of human solid tumors. To address this inconsistency, we performed a meta-analysis with 63 studies identified from PubMed, Medline and EBSCO. We found STAT3 overexpression was significantly associated with worse 3-year overall survival (OS) (OR = 2.06, 95% CI = 1.57 to 2.71, P < 0.00001) and 5-year OS (OR = 2.00, 95% CI = 1.53 to 2.63, P < 0.00001) of human solid tumors. Similar results were observed when disease free survival (DFS) were analyzed. Subgroup analysis showed that elevated STAT3 expression was associated with poor prognosis of gastric cancer, lung cancer, gliomas, hepatic cancer, osteosarcoma, prostate cancer, pancreatic cancer but better prognosis of breast cancer. The correlation between STAT3 and survival of solid tumors was related to its phosphorylated state. High expression level of STAT3 was also associated with advanced tumor stage. In conclusion, elevated STAT3 expression is associated with poor survival in most solid tumors. STAT3 is a valuable biomarker for prognosis prediction and a promising therapeutic target in human solid tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7887